---
title: Structural Variants PacBio Case Study | GENEWIZ from Azenta
description: GENEWIZ from Azenta utilized PacBio Sequel long-read technology to help a customer improve detection of structural variants within glioblastoma samples.
---

[Skip to content](https://web.genewiz.com/case-study/pacbio-sequel-structural-variants-glioblastoma#main-content)

[![GENEWIZ](https://web.genewiz.com/hubfs/GENEWIZ%20Brand%20Assets/GENEWIZ%20Logos/2025-04%20Current%20GENEWIZ%20Logos/GENEWIZ_Full-Color_Logo_PublicWeb_200x63.svg "GENEWIZ")](https://www.genewiz.com/)

 English

# PacBi® Sequel™ Sequencing Case Study

CASE STUDY

## Detection of Previously Unidentified Structural Variants Involved in Glioblastoma Using PacBio® Sequel™ Sequencing

Glioblastoma is a devastating disease due in part to its often late-stage diagnosis, rapid progression, and poor survival rates. This case study looks at how Azenta utilized the PacBio Sequel long-read technology to help a customer improve detection of structural variants within glioblastoma samples.

### This case study discusses:

- Generation of thousands of long-reads using PacBio Sequel Single Molecule Real Time (SMRT) technology
- Generation of highly accurate consensus sequences
- Identification of approximately 20,000 structural variants
- Future applications

![13044\_Pacbio\_LP-Thumbnail](https://web.genewiz.com/hs-fs/hubfs/_Current%20Azenta%20Thumbnails/13044_Pacbio_LP-Thumbnail.png?width=1220&height=1380&name=13044_Pacbio_LP-Thumbnail.png "13044_Pacbio_LP-Thumbnail")

## Download Case Study